Biomerica (BMRA) Liabilities and Shareholders Equity (2011 - 2026)

Biomerica has reported Liabilities and Shareholders Equity for 16 years, with the latest figure at $4.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 33.87% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $23.7 million (down 25.38% YoY) and the FY2025 annual result came in at $5.9 million, down 35.76% from the prior year.
• Liabilities and Shareholders Equity declined to $4.9 million in Q1 2026 per BMRA's latest filing, from $6.0 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $17.6 million in Q1 2022 and troughed at $4.9 million in Q1 2026.
• A 5-year average of $9.6 million and a median of $9.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity jumped 31.56% in 2022, then tumbled 53.25% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $9.9 million in 2022, then rose by 19.41% to $11.8 million in 2023, then slumped by 38.52% to $7.3 million in 2024, then fell by 17.05% to $6.0 million in 2025, then declined by 19.16% to $4.9 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $4.9 million, $6.0 million, and $6.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.